AcroMetrix Announces the Release of OptiQual(R) GBS Positive Control for Use with Diagnostic Assays That Detect Group B Streptococcus

BENICIA, Calif.--(BUSINESS WIRE)--AcroMetrix, a leading manufacturer of quality control standards and controls for clinical diagnostic and blood testing laboratories, announced today the release of the first standardized quality control for molecular Group B Streptococcus (GBS) testing. The OptiQual GBS Positive Control is designed to help clinical laboratories comply with CLIA guidelines for qualitative molecular assays that detect Group B Streptococcus DNA, ensuring accuracy and precision throughout the testing procedure.